OBJECTIVES: To assess the impact of etanercept (ETN) on quality-of-life (QoL) through 24 weeks in patients with moderate/severe psoriasis in specific countries of Central and Eastern Europe, Latin America, and Asia where data are limited. METHODS: Patients with moderate/severe psoriasis were randomized to 50mg ETN QW (once weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg QW (weeks 13-24). Patients completed the Dermatology Life Quality Index (DLQI) EuroQoL 5D (EQ-5D), FACT-Fatigue, HADS Anxiety Score, Psoriasis Subject Satisfaction Questionnaire, and Work Productivity Activity Impairment (WPAI) at baseline and subsequent visits.  RESULTS: Of 171 patients analysed, 85 were randomised to ETN BIW and 86 to ETN 50 QW. Baseline DLQI scores were 14.8 in both treatment groups suggesting severe QoL impairment. Significant improvements in DLQI from baseline were observed at weeks 12 and 24 in both groups (all p<0.0001); mean improvement at week 12 for ETN BIW was greater than for ETN QW (10.8 vs 8.4, p=0.001), but was similar between groups at week 24 (11.0 vs 9.5, p=0.063). EQ-5D utility was significantly improved from baseline in both groups at weeks 12 and 24 (all p<0.0001), with mean improvement significantly greater for the higher dose at both time-points (week 12: 0.3 vs. 0.2, p=0.029; week 24: 0.3 vs. 0.2, p=0.027). Mean EQ-5D improvement at week 24 was greater than MID (change ≥0.05) in a significantly greater proportion of patients receiving BIW than QW (77.1% vs 58.8%; p=0.013). Improvements of other patient-reported outcomes from baseline were observed at weeks 12 and 24 in both treatment groups. CONCLUSIONS: At baseline, patients had severely impaired QoL, and improvement in QoL was achieved with both ETN regimens. Improvements observed with ETN BIW were significantly greater than with ETN QW for both DLQI and EQ-5D utility at week 12, but only for EQ-5D at week 24.